Cervical cancer is the second most common cause of cancer deaths among women worldwide. It is the commonest cause of cancer deaths among Indian women. Every year, almost 74,000 women die due to cervical cancer in India. More than 130,000 Indian women are diagnosed with it every year. According to statistics, every hour 8 women in India die due to cervical cancer.

GARDASIL, the first vaccine to help prevent cervical cancer caused by the HPV types was launched today by Merck Sharp and Dohme (MSD), the indian affiliate of Merck & Co, Inc, US. The vaccine Gardasil is already available in 108 countries. 

According to company officials, GARDASIL is the only vaccine that helps protect against four types (Types 6, 11, 16, 18) of HPV.  

Dr Naveen A Rao, managing director, MSD India, said, "With the launch of GARDASIL, we have initiated the war against cervical cancer, the number one cause of mortality amongst Indian women due to cancer. MSD India will work with partners and communities to enhance awareness for the disease and access for the vaccine." 
 
Gardasil will be available at Rs 2,800 a shot. Three doses of this medicine are prescribed for efficacy.